Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?

Nicolas André, Kelvin Tsai, Manon Carré, Eddy Pasquier

研究成果: 雜誌貢獻回顧型文獻

19 引文 (Scopus)

摘要

Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. Here, we review and reappraise the fact that MC might be able to directly kill cancer cells. Although long neglected, this question is of critical importance both fundamentally and clinically, especially when considering future associations with immunotherapies.
原文英語
頁(從 - 到)319-325
頁數7
期刊Trends in Cancer
3
發行號5
DOIs
出版狀態已發佈 - 五月 1 2017

指紋

Drug Therapy
Neoplasms
Immunotherapy
Immune System
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Metronomic Chemotherapy : Direct Targeting of Cancer Cells after all? / André, Nicolas; Tsai, Kelvin; Carré, Manon; Pasquier, Eddy.

於: Trends in Cancer, 卷 3, 編號 5, 01.05.2017, p. 319-325.

研究成果: 雜誌貢獻回顧型文獻

André, Nicolas ; Tsai, Kelvin ; Carré, Manon ; Pasquier, Eddy. / Metronomic Chemotherapy : Direct Targeting of Cancer Cells after all?. 於: Trends in Cancer. 2017 ; 卷 3, 編號 5. 頁 319-325.
@article{7e91622e6389466a97c4f4b3e810f6fd,
title = "Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?",
abstract = "Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. Here, we review and reappraise the fact that MC might be able to directly kill cancer cells. Although long neglected, this question is of critical importance both fundamentally and clinically, especially when considering future associations with immunotherapies.",
keywords = "angiogenesis, chemotherapy, immunity, metronomic chemotherapy, stem cells",
author = "Nicolas Andr{\'e} and Kelvin Tsai and Manon Carr{\'e} and Eddy Pasquier",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.trecan.2017.03.011",
language = "English",
volume = "3",
pages = "319--325",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - Metronomic Chemotherapy

T2 - Direct Targeting of Cancer Cells after all?

AU - André, Nicolas

AU - Tsai, Kelvin

AU - Carré, Manon

AU - Pasquier, Eddy

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. Here, we review and reappraise the fact that MC might be able to directly kill cancer cells. Although long neglected, this question is of critical importance both fundamentally and clinically, especially when considering future associations with immunotherapies.

AB - Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. Here, we review and reappraise the fact that MC might be able to directly kill cancer cells. Although long neglected, this question is of critical importance both fundamentally and clinically, especially when considering future associations with immunotherapies.

KW - angiogenesis

KW - chemotherapy

KW - immunity

KW - metronomic chemotherapy

KW - stem cells

UR - http://www.scopus.com/inward/record.url?scp=85018647865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018647865&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2017.03.011

DO - 10.1016/j.trecan.2017.03.011

M3 - Review article

AN - SCOPUS:85018647865

VL - 3

SP - 319

EP - 325

JO - Trends in Cancer

JF - Trends in Cancer

SN - 2405-8033

IS - 5

ER -